Worsening after rituximab treatment in anti-mag neuropathy.
Laura
L
Broglio
Giuseppe
G
Lauria
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D018908:Muscle Weakness / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D011115:Polyneuropathies / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069283:Rituximab; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D018992:Myelin-Associated Glycoprotein; D000069283:Rituximab